My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    (S)-Thalidomide
    (S)-Thalidomide

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V3395
    CAS #: 841-67-8 [(S)-Thalidomide]; 50-35-1 (racemic); 2098488-36-7 (Azido-Thalidomide)Purity ≥98%

    Description: (S)-Thalidomide is the S-enantiomer of thalidomide (brand name Immunoprin) which is an immunomodulatory agent and the prototypic drug of the thalidomide class of drugs that are used mainly for the treatment of certain cancers (e.g. MM-multiple myeloma) and of a complication of leprosy. It was introduced as a sedative drug, immunomodulatory agent in 1950s by the German pharmaceutical company Grunenthal and also is investigated for treating symptoms of many cancers. Nowadays, Thalidomide is often times used as a PROTAC (Proteolysis Targeting Chimera) building block which acts as a ligand for the E3 ubiquitin ligase cereblon. PROTAC is a technology utilizes hetero-bifunctional small molecules whereby one end of the molecule recruits an E3 ubiquitin ligase while the other end engages the target protein. Thalidomide inhibits an E3 ubiquitin ligase, which is a CRBN-DDB1-Cul4A complex. Thalidomide is a potent costimulator of primary human T cells in vitro, synergizing with stimulation via the T cell receptor complex to increase interleukin 2-mediated T cell proliferation and interferon gamma production.

    References: [1] Hideshima T, et al. Blood, 2000, 96(9), 2943-2950.[2] Haslett PA, et al. J Exp Med, 1998, 187(11), 1885-1892.

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)258.23
    FormulaC13H10N2O4
    CAS No.50-35-1 (racemic); 841-67-8 [(S)-Thalidomide]; 2098488-36-7 (Azido-Thalidomide)
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 52 mg/mL (201.37 mM)
    Water:<1 mg/mL (slightly soluble or insoluble)
    Ethanol: 2 mg/mL (7.74 mM)
    Solubility (In vivo)30% PEG400+0.5% Tween80+5% Propylene glycol: 5 mg/mL
    Chemical Name(S)-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione
    Synonyml-Thalidomide; NSC 91730; NSC-91730; NSC91730; Brand names: Synovir; Thalomid (US); Foreign brand names: Contergan; Distaval; Kevadon; Neurosedyn; Pantosediv; Sedoval K17; Softenon Talimol; alphaphthalimidoglutarimide. Nphthaloylglutamimide; Nphthalylglutamic acid imide.


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In VitroThalidomide must be metabolized by the liver to form an epoxide that may be the active teratogenic metabolite. Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor alpha (TNF-alpha) when human monocytes are triggered with lipopolysaccharide and other agonists in culture.
    In VivoThalidomide (100 mg/kg, p.o.) inhibits the collagen deposition, down-regulates the mRNA expression level of α-SMA and collagen I, and significantly reduces the pro-inflammatory cytokines in RILF mice. Thalidomide alleviates RILF via suppression of ROS and down-regulation of TGF-β/Smad pathway dependent on Nrf2 status. Thalidomide (200 mg/kg, p.o.) combined with icotinib shows synergistic anti-tumor effects in nude mice bearing PC9 cells, suppressing tumor growth and promoting tumor death.
    Animal modelC57BL/6 mice
    Formulation & Dosage100 mg/kg, p.o.
    References[1] D Amato RJ, et al. Proc Natl Acad Sci U S A, 1994, 91(9), 4082-4085. ; Free Radic Biol Med. 2018 Dec;129:446-453.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?